Merck Stock Slumps as Q4 Profits, forecast 2025 is not short

Merck shares fell on Tuesday morning after soft drug forecasts, which achieved revenues from the fourth quarter that achieved expectations.

Merck (MRK) reported $ 15.62 billion for a quarter, which is an increase of 7% year -on -year and above $ 15.43 billion, in accordance with the estimates developed by Visible Alpha. The company’s net income was USD 3.74 billion, i.e. $ 1.48 per share, compared to a loss of $ 1.2 billion a year ago, but below $ 3.92 billion.

However, after correcting one -off fees, such as costs related to acquisitions, Merck’s corrected net income in the amount of $ 4.37 billion exceeded the estimates of USD 4.21 billion.

2025 perspectives are significantly without estimates

In the case of 2025, Maker expects revenues from 64.1 billion to USD 65.6 billion, with a forecast of corrected profit per share from 8.88 to 9.03 USD per share. Analysts had higher expectations, with the current consensus 2025 at USD 67.08 billion of revenues and 9.09 USD of corrected EPS.

Sales increased in most Merck Portfolio, and the sales of Gardasil and Januvia fell asked to the lower demand in some international regions and lower prices in the USA.

Merck shares fell by over 10% on Tuesday morning.